Belantamab mafodotin 100mg powder for solution for infusion vials
NHS hospitals in England used £48,644,510 of indicative cost of Belantamab mafodotin 100mg powder for solution for infusion vials in the 12 months to April 2026, about 0.2% of all hospital medicines spend. That is up 316.4% on the previous 12 months.
Indicative cost · 12 months
Quantity (VMP units) · 12 months
Share of hospital medicines spend
Figure 1. Belantamab mafodotin 100mg powder for solution for infusion vials: NHS hospital indicative cost by month (£ millions)
Source: NHSBSA Secondary Care Medicines Data, to April 2026
Cost is indicative — actual hospital medicine prices are commercially confidential, so these figures are estimated from list prices. See methodology.
NHS trusts using Belantamab mafodotin 100mg powder for solution for infusion vials most
By indicative cost over the 12 months to April 2026.
| NHS trust | Indicative cost (12 months) |
|---|---|
| The Royal Marsden Nhs Foundation Trust | £3,238,128 |
| University College London Foundation Tr | £2,178,360 |
| Sheffield Teaching Hospitals Nhs Trust | £1,960,992 |
| United Lincolnshire Hospitals Nhs Trust | £1,920,672 |
| Imperial College Healthcare Nhs Trust | £1,875,096 |
| Cambridge Univ Hosp Nhs Foundation Trust | £1,617,408 |
| Univ Hpl B/Ham Nhs Foundation Trust | £1,602,216 |
| Northumbria H/Care Nhs Foundation Trust | £1,592,088 |
| University Hospital Southampton Nhs Ft | £1,388,256 |
| University Hpls Of Leicester Nhs Trust | £1,366,344 |
The primary-care picture
No confident match to a community-dispensed medicine was found for this product, so no primary-care comparison is shown. SCMD products are recorded at product level, which does not always map cleanly to a BNF substance.